Академический Документы
Профессиональный Документы
Культура Документы
Terry Grossman,M.D. Medical Director Morris Johnson, CTO, Founder Silas Kanning,
Co-founders of:
Lifespan Pharma Inc.
Morris/Greg/Leah/Erin
Rod Fisher
Steve Burnside
REBRANDING HEMP AS CANTERPENE MAKES SENSE FOR THE NATURAL HEALTH PRODUCT / DSHEA FOOD SUPPLEMENT MARKETS
35 YEARS AGO RAPESEED EXPERIENCED THE SAME PROBLEMS AFFECTING HEMP TODAY
Growers needed to rebrand something that was associated with a machine oil regarded as too toxic for humans to consume
It was promoted as a safe, nutritious, multipurpose human and animal food ingredient
When you Google hemp you get recreational and medicinal marijuana Hits because pot people use hemp indiscriminately when speaking about marijuana
SOME MARIJUANA PRODUCTS associate cannabis with health benefits and socially sexy memes such as organic or chemical free
Ignore?
AFTER MUCH CONSIDERATION WE CONCLUDED NONE OF THE ABOVE SOLUTIONS ARE PRACTICAL OR COST EFFECTIVE
Some hemp manufacturers want to capitalize on the science which has popularized the term Medical Marijuana The best solution: REBRANDING
This
Becomes
This--> All Too Soon
AT ANY AGE
60 yrs old
80 yrs old
Prevention
Early Detection
Canterpene captures much that other conventional hemp supplements have ignored
A toolbox for slowing aging & regenerating damage is emerging: e.g. Plastoquinine..targeting oxidative stress
CANTERPENE
Parkinsons
Alzheimers
Cannabidiol (CBD) the major cannabinoid in hemp has been shown to be of benefit in each of these and many other conditions
OXIDATIVE STRESS
CBD treatment significantly reduced oxidative stress; decreased the levels of tumor necrosis factor, vascular endothelial growth factor, and intercellular adhesion molecule-1; and prevented retinal cell death and vascular hyperpermeability in the diabetic retina. Consistent with these effects, CBD treatment also significantly inhibited p38 MAP kinase in the diabetic retina. These results demonstrate that CBD treatment reduces neurotoxicity, inflammation, and BRB breakdown in diabetic animals. EL Remessey AB et al. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol. 2006 Jan;168(1):235-44.
ARTHRITIS
These potentially anti-inflammatory properties of CBD, together with the lack of psychotropic effect and low toxicity prompted us to test the potential of CBD as a therapeutic agent in collagen-induced arthritis (CIA). RESULTS: We report that CBD has a beneficial therapeutic action on established CIA.
Malfait AM et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9561-6.
PARKINSONS DISEASE
Evidence suggests that cannabinoids may prove useful in Parkinson's disease by inhibiting the excitotoxic neurotransmitter glutamate and counteracting oxidative damage to dopaminergic neurons Croxford JL. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs. 2003;17(3):179-202. It seems that cannabinoids could delay or even stop progressive degeneration of brain dopaminergic systems, a process for which there is presently no prevention. In combination with currently used drugs, cannabinoids might represent, qualitatively, a new approach to the treatment of PD, making it more effective. Sevcik J, Masek K Potential role of cannabinoids in Parkinson's disease DRUG AGING 16 (6): 391-395 JUN 2000
ALZHEIMERS DISEASE
Memory loss, the first and primary symptom of Alzheimers disease, can be slowed down significantly in mice by cannabidiol. In a study at the Cajal Institute in Madrid, Spain, mice were injected with a molecule found in the brain of humans suffering from Alzheimers disease, and then treated for one week with cannabidiol. Those mice injected with cannabidiol successfully performed the task within 25-30 seconds, compared to control mice, who took almost double the amount of time, 45-50 seconds, to complete the task. See also: Iuvone T, Esposito G, Esposito R, et al. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells J NEUROCHEM 89 (1): 134-141 APR 2004
Lifespan Pharma Inc SW34-01-16-W2nd meridian Box 10 Beaubier, Sk., CANADA Lifespan.pharma.inc@gmail.com 701-240-9411
Presented at : Canadian Hemp Trade Alliance Nov 15-17, 2010 Annual Conference Winnipeg , Manitoba , Canada